Finance

Lists
Why is SGIOY up 4,10%?
Dive Deeper
SGIOY:OTCMKTS
Shionogi 2 ADR Representing 1 Ord Shs
9,13 USD
+4,10%
(+0,36) 1D
15-окт., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SGIOY...
Open
9,53 USD
High
9,53 USD
Low
8,95 USD
Mkt. cap
2,61 трлн
Avg. vol.
172,76 миң
Volume
120,07 миң
52-wk high
12,00 USD
52-wk low
7,83 USD
Beta
0,07
Shares outstanding
1,78 млд
No. of employees
6 миң
Open
9,53 USD
High
9,53 USD
Low
8,95 USD
Mkt. cap
2,61 трлн
Avg. vol.
172,76 миң
Volume
120,07 миң
52-wk high
12,00 USD
52-wk low
7,83 USD
Beta
0,07
Shares outstanding
1,78 млд
No. of employees
6 миң
News stories
From web sources and news partners
ad-hoc-news.de
ad-hoc-news.de
·
12 саат мурун
Jefferies sets JPY 3,900.00 target for Shionogi stock
Profile
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana. Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines. In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan. Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV. The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index. In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
About Shionogi 2 ADR Representing 1 Ord Shs
CEOIsao Teshirogi
Employees6,22 миң
Founded1878
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
113,18 млд
147,72 млд
138,99 млд
163,31 млд
Cost of goods sold
16,94 млд
25,09 млд
28,10 млд
30,80 млд
Cost of revenue
16,94 млд
25,09 млд
28,10 млд
30,80 млд
Research and development expenses
27,55 млд
29,87 млд
40,54 млд
31,79 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27,56 млд
35,27 млд
32,92 млд
44,36 млд
Operating expense
56,57 млд
48,45 млд
100,06 млд
113,87 млд
Total operating expenses
73,51 млд
73,54 млд
128,17 млд
144,66 млд
Operating income
39,67 млд
74,18 млд
10,83 млд
18,64 млд
Other non operating income
-
-1,00 млн
7,31 млд
-2,00 млн
EBT including unusual items
52,06 млд
92,89 млд
47,64 млд
73,74 млд
EBT excluding unusual items
52,06 млд
93,10 млд
47,80 млд
25,47 млд
Income tax expense
7,87 млд
18,21 млд
-56,00 млн
-23,98 млд
Effective tax rate
15,12%
19,60%
-0,12%
-32,52%
Other operating expenses
979,00 млн
-17,25 млд
15,44 млд
21,90 млд
Net income
44,19 млд
74,68 млд
46,93 млд
97,70 млд
Net profit margin
39,04%
50,56%
33,77%
59,82%
Earnings per share
-
-
-
-
Interest and investment income
14,21 млд
20,53 млд
23,73 млд
12,15 млд
Interest expense
-1,82 млд
-1,61 млд
-
-5,32 млд
Net interest expenses
12,38 млд
18,92 млд
23,73 млд
6,82 млд
Depreciation and amortization charges
-485,00 млн
-
-1,53 млд
-
EBITDA
44,83 млд
80,21 млд
21,59 млд
39,52 млд
Gain or loss from assets sale
-
-
35,04 млд
-
AI content may include mistakes. Learn more
Google колдонмолору